Inovio Pharmaceuticals (INO) has risen sharply, recording gains of 2.64% in the past 4 weeks. However, the stock has corrected -1.89% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.2% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.29% and the 50-Day Moving Average is 0.8%.The 200 Day SMA reached 9.5%
Inovio Pharmaceuticals (NASDAQ:INO): After opening at $9.28, the stock dipped to an intraday low of $9.15 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $9.46 and the buying power remained strong till the end. The stock closed at $9.32 for the day, a gain of 0.65% for the day session. The total traded volume was 876,626. The stocks close on the previous trading day was $9.32.
Inovio Pharmaceuticals (INO) stock is expected to deviate a maximum of $7.8 from the average target price of $19.75 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $31 and the most muted being $13.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.